Equities researchers at CL King began coverage on shares of Bio-Rad Laboratories Inc. (NYSE:BIO) in a research report issued on Wednesday. The firm set a “buy” rating on the stock.

BIO has been the subject of a number of other reports. Jefferies Group boosted their price objective on shares of Bio-Rad Laboratories from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, September 7th. Zacks Investment Research upgraded shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, July 6th.

Shares of Bio-Rad Laboratories (NYSE:BIO) traded down 0.44% during trading on Wednesday, reaching $161.06. The company’s stock had a trading volume of 129,822 shares. The company has a market capitalization of $4.74 billion, a price-to-earnings ratio of 48.85 and a beta of 0.87. Bio-Rad Laboratories has a one year low of $122.03 and a one year high of $164.89. The firm’s 50-day moving average price is $158.02 and its 200-day moving average price is $147.67.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, August 3rd. The company reported $0.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.13 by $0.52. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 4.79%. The firm earned $516.80 million during the quarter, compared to analysts’ expectations of $497.80 million. During the same quarter in the previous year, the firm earned $0.97 earnings per share. Bio-Rad Laboratories’s revenue was up 2.1% on a year-over-year basis. On average, equities analysts anticipate that Bio-Rad Laboratories will post $3.10 earnings per share for the current year.

Large investors have recently made changes to their positions in the stock. Advisors Asset Management Inc. raised its stake in shares of Bio-Rad Laboratories by 22.3% in the second quarter. Advisors Asset Management Inc. now owns 734 shares of the company’s stock worth $105,000 after buying an additional 134 shares in the last quarter. Advisor Group Inc. bought a new stake in shares of Bio-Rad Laboratories during the second quarter worth $108,000. Barclays PLC raised its stake in shares of Bio-Rad Laboratories by 48.8% in the second quarter. Barclays PLC now owns 1,052 shares of the company’s stock worth $149,000 after buying an additional 345 shares in the last quarter. Meeder Asset Management Inc. raised its stake in shares of Bio-Rad Laboratories by 10,254.5% in the first quarter. Meeder Asset Management Inc. now owns 1,139 shares of the company’s stock worth $156,000 after buying an additional 1,128 shares in the last quarter. Finally, Creative Planning raised its stake in shares of Bio-Rad Laboratories by 14.0% in the third quarter. Creative Planning now owns 1,007 shares of the company’s stock worth $165,000 after buying an additional 124 shares in the last quarter. Institutional investors and hedge funds own 62.82% of the company’s stock.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

5 Day Chart for NYSE:BIO

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.